Research supported by the NIHR Birmingham BRC will build on world-leading discovery science expertise and our outstanding track-record of translation to clinical benefit.

Our research programme focuses on inflammation and the diagnosis, prevention and treatment of its associated long-term illnesses. Our research themes focus on illnesses, processes and methodologies. They will share technologies, infrastructure, knowledge and perspectives across themes, to create truly multi-disciplinary solutions to enduring societal, health and research challenges.

Six illness-specific themes (Arthritis; Infection & Acute Care; Liver Disease; Women’s Metabolic Health; Cancer Inflammation; Oral, Intestinal & Systemic Health) are complemented by process-specific themes (Thrombo-inflammation; Sarcopenia & Multimorbidity). All themes will leverage innovative methodologies within our Data, Diagnostics & Decision Tools, Patient Reported Outcomes and Next Generation Therapies themes.

Diagram featuring all the 11 Birmingham BRC research themes in a circle surrounding a diagram of eight heads of people of different genders, ages, and ethnicities.

All themes:

  • Reflect existing partnerships, excellence and track record;
  • Include defined project portfolios translating anticipated/emerging scientific breakthroughs to deliver clinical benefits;
  • Focus on questions that reflect direct patient need and respect community diversity;
  • Are informed by patient/public partnership and prioritisation, from design to delivery;
  • Will deliver innovations leading to new candidate therapies, improved care approaches and commercialisable technologies;
  • Will generate data and publications to be shared openly, via FAIR-compliant data repositories and open-access publication.

We will apply common experimental approaches, tissue resources, technologies and data platforms to investigate mechanisms of inflammation across different themes, organs and illnesses. We will nurture links  between themes, identify multi-disciplinary opportunities and create new collaborations. This will ensure new innovations can be translated from our strong discovery science pipeline into tangible patient benefit.